Alembic Pharma gets USFDA nod for generic antidepressant drug

The company currently has a total of 53 ANDA approvals from the US health regulator

Press Trust of India  |  New Delhi 

Alembic Pharmaceuticals has received approval from the US health regulator for generic Fluoxetine Hydrochloride tablets used for the treatment of depression and panic disorder.

The approval is for the generic version of and Company's Prozac tablets in the same strengths, said in a BSE filing today.

The tablets are indicated for treatment of major depressive disorder and obsessive compulsive disorder in adult and paediatric patients, it said.

They are also indicated for treatment of binge-eating and vomiting behaviour in moderate to severe Bulimia Nervosa and acute treatment of panic disorder, in adult patients.

"The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application for Fluoxetine Hydrochloride tablets, 10 mg and 20 mg", it said.

These tablets have an estimated market size of $120 million for 12 months ending December 2015 according to IMS, the company added.

currently has a total of 53 ANDA approvals from the US health regulator.

The company's stock was trading 0.84 per cent higher at Rs 625 per scrip on BSE today.

Alembic Pharma gets USFDA nod for generic antidepressant drug

The company currently has a total of 53 ANDA approvals from the US health regulator

The company currently has a total of 53 ANDA approvals from the US health regulator
Alembic Pharmaceuticals has received approval from the US health regulator for generic Fluoxetine Hydrochloride tablets used for the treatment of depression and panic disorder.

The approval is for the generic version of and Company's Prozac tablets in the same strengths, said in a BSE filing today.

The tablets are indicated for treatment of major depressive disorder and obsessive compulsive disorder in adult and paediatric patients, it said.

They are also indicated for treatment of binge-eating and vomiting behaviour in moderate to severe Bulimia Nervosa and acute treatment of panic disorder, in adult patients.

"The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application for Fluoxetine Hydrochloride tablets, 10 mg and 20 mg", it said.

These tablets have an estimated market size of $120 million for 12 months ending December 2015 according to IMS, the company added.

currently has a total of 53 ANDA approvals from the US health regulator.

The company's stock was trading 0.84 per cent higher at Rs 625 per scrip on BSE today.
image
Business Standard
177 22